ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana, …
Post
-
-
Tempus’ automated alerts boost patient outcomes in valvular heart disease
Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting …
-
Data shows 6.7% of global clinical trials impacted by Middle East disruption
An analysis of 65,061 globally recruiting clinical trials across 186 countries finds that 4,361 studies, equivalent to 6.7% of all …
-
Agenus enrols first patient in BATTMAN Phase III trial
Agenus has enrolled the first patient in the BATTMAN Phase III trial, assessing botensilimab (BOT) plus balstilimab (BAL) in refractory, …
-
Actinogen treats first patient in XanaMIA trial for Alzheimer’s
Actinogen has treated the first participant in the open-label extension (OLE) segment of its Phase IIb/III pivotal XanaMIA Alzheimer’s disease …
-
Oric to advance prostate cancer drug to Phase III trials
ORIC Pharmaceuticals will advance its prostate cancer drug to Phase III trials after it showed survival benefit in a Phase …
-
EMA backs virtual animal control as preclinical NAM amid animal testing phaseout
The European Medicines Agency (EMA) has issued a fresh blueprint on the use of new approach methodologies (NAMs) amid its …
-
Meningitis outbreak in UK suggests vigilance is required even if cases are rare
The UK is currently facing a meningitis outbreak, especially in the younger population. The outbreak started in Kent, south-east of …
-
LabConnect unveils SampleGISTICS 2.0 for trial sample digitisation
LabConnect has introduced the smartphone-based SampleGISTICS 2.0 application to digitise clinical trial sample capture. With the new application, clinical research staff will be …
-
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa
AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic …
-
ACC 2026: pooled analysis supports early dapagliflozin use in acute HF care
On 30 March, at this year’s American College of Cardiology (ACC) Scientific Session, during a poster contributions session on the …
-
Boston Scientific presents Watchman FLX and EKOS endovascular system data
Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial appendage …
-
MoonLake’s lead asset shows durability in late-stage HS studies
MoonLake Immunotherapeutics’ targeted therapy, sonelokimab, has offered long-term disease-modifying and quality of life (QoL)-boosting benefits during two Phase III hidradenitis …
-
MSD boasts data for oral PCSK9 inhibitor as add on therapy
MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has reduced low-density lipoprotein cholesterol (LDL-C) levels when combined with background …
-
Idorsia reports positive data for paediatric insomnia study of daridorexant
Idorsia has reported positive top-line data from its Phase II dose-finding trial evaluating daridorexant, a dual orexin receptor antagonist, for …
